WuXi Biologics Expands GMP Network with 18th Drug Product Facility

Event summary

  • WuXi Biologics' Drug Product Facility 15 (DP15) in Shanghai achieved GMP release in April 2026, becoming the company's 18th operational drug product facility.
  • DP15 is equipped with advanced isolator-based aseptic filling lines, supporting both liquid and lyophilized drug product manufacturing.
  • The facility has already completed multiple engineering and GMP batches, delivering clinical supplies for regulatory filings.
  • WuXi Biologics operates 18 drug product facilities and 24 drug substance facilities globally, with over 13,000 employees.

The big picture

WuXi Biologics' expansion of its GMP network underscores the growing demand for integrated drug substance to drug product capabilities in the biologics sector. The company's global footprint and consistent regulatory success position it as a key player in accelerating biologic drug development, particularly as complex modalities become more prevalent in the industry.

What we're watching

Capacity Utilization
How quickly WuXi Biologics fills DP15 with client projects, given its existing portfolio of 945 integrated client projects.
Regulatory Momentum
Whether the company can maintain its 100% success rate in regulatory inspections as it expands its global network.
Technological Integration
The pace at which WuXi Biologics integrates advanced technologies like WuXiHigh™ and hyaluronidase co-formulation into new facilities.